National Comprehensive Cancer Network® (NCCN®) Guidelines recommend pralsetinib (GAVRETO) as a first-line treatment option for RET-positive metastatic NSCLC (category 2A).2

Learn more about GAVRETO

GAVRETO Product Brochure

Product Brochure

Download PDF
Patient Support and Savings

Patient Support
and Savings

Learn More
GAVRETO Order Sheet

Order Sheet

Download PDF
GAVRETO Dosing & Administration Guide

GAVRETO Dosing &
Administration Guide

Download PDF

Connect with us or register for updates

Register here to receive information about GAVRETO or meet with one of our GAVRETO specialists at your convenience.

Please enter your first name
Please enter your last name
Please enter your email address in the following format:
Your email addresses do not match. Please confirm your email address.

By checking this box, you confirm that you are a U.S. healthcare professional and agree to be contacted by a representative of Blueprint Medicines.

Please enter your zip code in a valid format: 12345

Response required

*Required fields.

Success—your form has been submitted

Thank you for your interest in GAVRETO.

Getting your patients started on GAVRETO with YourBlueprint:
A support program for your patients

YourBlueprint is a patient support program designed with your patients’ care in mind. YourBlueprint assists patients throughout many aspects of treatment by providing:

Financial assistance options

assistance options*

Prior authorization and appeals support

Prior authorization
and appeals support

Benefits investigation

Benefits investigation

Click below for information on how to enroll your patient in YourBlueprint today.

Enroll Your Patients

1-888-BLUPRNT (1-888-258-7768)

Monday–Friday 8AM–8PM Eastern Time (ET)

*For terms and conditions, call 1-888-BLUPRNT (1-888-258-7768).

GAVRETO Co-pay assistance program

Co-pay assistance program

This program helps eligible, commercially insured patients reduce their out-of-pocket costs (co-pay, co-insurance, or deductible) to as little as $0.
For more information, see the full Terms and Conditions.

Enroll your patient in the co-pay assistance program today.

Apply Now

NSCLC=non–small cell lung cancer; RET=rearranged during transfection.


GAVRETO™ (pralsetinib) is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information

Pneumonitis occurred in 10% of patients who received GAVRETO, including 2.7% with Grade 3/4, and 0.5% with fatal reactions. Monitor for pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD.

Hypertension occurred in 29% of patients, including Grade 3 hypertension in 14% of patients. Overall, 7% had their dose interrupted and 3.2% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue GAVRETO based on the severity.

Hepatotoxicity: Serious hepatic adverse reactions occurred in 2.1% of patients treated with GAVRETO. Increased AST occurred in 69% of patients, including Grade 3/4 in 5.4% and increased ALT occurred in 46% of patients, including Grade 3/4 in 6%. The median time to first onset for increased AST was 15 days (range: 5 days to 1.5 years) and increased ALT was 22 days (range: 7 days to 1.7 years). Monitor AST and ALT prior to initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on severity.

Grade ≥ 3 hemorrhagic events occurred in 2.5% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event. Permanently discontinue GAVRETO in patients with severe or life-threatening hemorrhage.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, GAVRETO has the potential to adversely affect wound healing. Withhold GAVRETO for at least 5 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution of wound healing complications has not been established.

Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the final dose. Advise women not to breastfeed during treatment with GAVRETO and for 1 week after the final dose.

Common adverse reactions (≥25%) were fatigue, constipation, musculoskeletal pain, and hypertension.
Common Grade 3-4 laboratory abnormalities (≥2%) were decreased lymphocytes, decreased neutrophils, decreased phosphate, decreased hemoglobin, decreased sodium, decreased calcium (corrected) and increased alanine aminotransferase (ALT).

Avoid coadministration with strong CYP3A inhibitors. Avoid coadministration of GAVRETO with combined P-gp and strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the GAVRETO dose. Avoid coadministration of GAVRETO with strong CYP3A inducers. If coadministration cannot be avoided, increase the GAVRETO dose.

Please click here to see the full Prescribing Information for GAVRETO.

Reference: 1. GAVRETO™ (pralsetinib). Prescribing Information. Blueprint Medicines Corporation; Cambridge, MA. September 2020.